Sorry, you need to enable JavaScript to visit this website.
Skip to main content

Location Settings

Asia-Pacific

AU -  Sydney
AU -  Melbourne
AU -  Brisbane
CN -  Hong Kong
CN -  Shanghai
IN -  Bangalore
MY -  Kuala Lumpur
PH -  Metro Manila
KR -  Seoul
CN -  Taipei City
TH -  Bangkok
NZ -  New Zealand

North America

US -  Boston

GLOBAL

English

CAREERS

SOLUTIONS

RESOURCES

ABOUT US

Location Settings

Asia-Pacific

AU -  Sydney
AU -  Melbourne
AU -  Brisbane
CN -  Hong Kong
CN -  Shanghai
IN -  Bangalore
MY -  Kuala Lumpur
PH -  Metro Manila
KR -  Seoul
CN -  Taipei City
TH -  Bangkok
NZ -  New Zealand

North America

US -  Boston

GLOBAL

English

Novotech Showcases Asia-Pacific Success as a Rare Diseases Clinical Trial Hub

Novotech Showcases Asia-Pacific Success as a Rare Diseases Clinical Trial Hub

September 20,2021

Hong Kong - Novotech, a leading biotech specialist CRO in the Asia-Pacific region this month showcases its rare diseases expertise in a new ARENA webinar titled Understanding Asia’s Success as a Rare Diseases Clinical Trial Location, and a keynote presentation at the Clinical Trials in Rare Diseases Conference 2021 (September 14, virtual).

  • The Understanding Asia’s Success as a Rare Diseases Clinical Trial Location webinar is available to view here: https://novotech-cro.com/webinars/accelerating-clinical-trials-rare-disease-understanding-asias-success-rare-disease.
  • Novotech’s Team Lead Client Operations Kirsten Kinsey’s presented Rare Disease Program Success in APAC at Clinical Trials in Rare Diseases Conference 2021. 

There are up to 8,000 rare diseases affecting between 6% and 8% of the worldwide population in total. It is estimated there are about 25 to 30 million people affected in the US while over 45 million people may be suffering from a rare condition in Asia, with 20 million in China alone.

Despite the large number of known orphan diseases, it is estimated only about 5% of rare diseases have an approved treatment.

The webinar looks at Asia’s rare disease clinical trial landscape, and China’s increasing popularity as a clinical trial location, to understand the regional advantages on offer. The panel discusses their first-hand experiences and insights working on range of rare disease programs from a clinical trial operations perspective. They also share the challenges and critical program strategies that need to be considered to support accelerating a clinical program development in the rare disease space.


About 25% of drugs granted with an orphan designation since 2015 were concentrated on 10 major indications. For most of these indications, clinical studies involving sites from Asia-Pacific outperformed the median patient enrollment duration of rare disease trials globally.

Asian countries have been implementing legal frameworks similar to the Orphan Drug Act used in the US, encouraging clinical trials in many locations including South Korea, Taiwan, Singapore and the Philippines.

These new legal frameworks in Asia offer general criteria to accelerate the registration and approvals of drugs for the treatment of rare diseases and have established new rules concerning health insurance coverage, expedited registration, and marketing exclusivity periods for biopharma companies.
 
Furthermore, the Action Plan on Rare Diseases launched by the Asia-Pacific Economic Cooperation is expected to accelerate supportive actions to develop public actions, disease registries, and patient access to clinical trials, and to reduce enrollment durations.

Rare disease clinical studies require a CRO with local knowledge across the Asia-Pacific regulatory, cultural and clinical processes as well as proven networks with specialist clinical leaders and organizations.

This includes expertise in site selection and access to patient registries to accelerate patient enrolment, and global regulatory knowledge regarding the specific context of rare disease trials and orphan diseases trials.

The Asia-Pacific region is the fastest growing region in the global CRO market, offering access to vast patient populations, quality data and expedited regulatory processes.

Novotech has just been awarded the ‘2021 Frost & Sullivan Asia-Pacific CRO Company of the Year’. This is the fifth consecutive year that Novotech has been recognized with the prestigious CRO regional award. 

 

Media Contact

David James

communications@novotech-cro.com

AU: +61 2 8218 2144 

USA: +1 415 951 3228

Asia: +65 3159 3427

ABOUT NOVOTECH HEALTH HOLDINGS 

Novotech Health Holdings Pte. Ltd. (“Novotech Holdings”) is a leading Asia-Pacific biotech specialist CRO and consists of two operating brands, Novotech and PPC. Novotech Holdings is a full-service CRO with integrated labs and phase I facilities providing drug development consulting and clinical development services. It has been instrumental in the success of approximately 3,700 clinical trials across all trial phases and broad range of therapeutic areas. Novotech Holdings is well positioned to serve biopharmaceutical clients conducting clinical trials in Asia and globally. As of March 31, 2021, we had a total of 1,765 FTEs working across our offices in 11 geographies in Asia-Pacific and the United States.

For more information, visit https://novotech-holdings.com/ 

close HOLD THE DATE! Oct 21, 2021, Endpoint Webinar on driving efficiencies through virtual trial solutions in Asia Pacific.